

Medi Lifestyle to Raise Approximately S\$8.75 Million through Placement of 178,588,000 New Ordinary Shares

- **Medi Lifestyle expects to raise gross proceeds of approximately S\$8.75 million through the placement of 178,588,000 new ordinary shares**
- **The Placement Shares will be issued at S\$0.049 per share, raising gross proceeds of S\$8,750,812**
- **Net proceeds will mainly use to support the Company's working capital requirements, business development and expansion opportunities**
- **The Placement strengthens Medi Lifestyle's financial flexibility as it advances its strategic growth plans**

Singapore, 18 August 2026 — Medi Lifestyle Limited (the "Company" or "Medi Lifestyle"), a diversified outsourced services and commodity trading group listed on the Catalist board of the Singapore Exchange Securities Trading Limited ("SGX-ST"), is pleased to announce the placement of 178,588,000 new ordinary shares in the capital of the Company (the "Placement Shares") at an issue price of S\$0.049 per Placement Share (the "Placement").

The Placement will raise gross proceeds of approximately S\$8.75 million. After deducting estimated expenses relating to the Placement, the Company expects to receive net proceeds of approximately S\$8.59 million to support its business expansion and strategic growth initiatives.

Placement Details

The Placement Shares represent approximately 31.49% of the Company's issued and paid-up share capital immediately before completion of the Placement and approximately 23.95% immediately after completion.

The Placement Shares will be issued pursuant to the general share issue mandate obtained from shareholders at the Company's annual general meeting held on 30 April 2026. Upon allotment and issue, the Placement Shares will rank *pari passu* in all respects with the existing ordinary shares in the capital of the Company, except for any dividends, rights, allotments or



other distributions for which the record date falls on or before the date of the date of completion of the Placement.

The Company will submit, through its Sponsor, an application to the SGX-ST for the listing and quotation of the Placement Shares on the Catalist board of the SGX-ST. The Company will make the relevant announcement upon receipt of the listing and quotation notice from the SGX-ST.

Use of Proceeds

After deducting estimated expenses of approximately S\$0.16 million, the Company expects to receive net proceeds of approximately S\$8.59 million from the Placement.

The Company intends to apply approximately S\$0.46 million, representing 5% of the net proceeds, towards the repayment of a shareholder's loan; approximately S\$2.12 million, representing 25% of the net proceeds, towards general working capital, including administrative expenses, manpower costs, compliance costs, continuing listing expenses, professional fees and general overheads; and approximately S\$6.01 million, representing 70% of the net proceeds, towards business development and expansion opportunities, including new project financing, strategic investments, mergers and acquisitions, and strategic partnerships. Pending deployment, the net proceeds may be placed as deposits with financial institutions or invested in short-term, interest-bearing instruments.

Strategic Rationale

The Placement will strengthen the Company's financial position by supporting the repayment of a shareholder's loan, reinforcing its working capital base and providing capital for business development and expansion opportunities. These may include new project financing, strategic investments, mergers and acquisitions, and strategic partnerships. The additional capital will give Medi Lifestyle greater flexibility to evaluate and pursue opportunities while maintaining sufficient resources for its ongoing operating and listing requirements.

The Company also hopes to broaden the Company's shareholder base, as well as to improve trading liquidity of the Shares with an enlarged shareholder base.

The Company will provide shareholders with appropriate updates on the use of the net proceeds in accordance with the requirements of the Catalist Rules.

Additional Information

Further details relating to the Placement are set out in the Company's announcement released on 17 August 2026 on SGXNET.

Mr Tan Lee Seng, Executive Director and Chief Executive Officer of Medi Lifestyle, said:

“This Placement strengthens our financial foundation and provides additional capacity to advance Medi Lifestyle’s growth plans. We intend to deploy the proceeds prudently—supporting our working capital needs while pursuing business development opportunities, strategic investments and partnerships that can create sustainable long-term value for shareholders.”

#END#

About Medi Lifestyle Limited

Medi Lifestyle Limited (SGX: Z4D) is an SGX Catalist-listed investment holding company diversified across high-growth business services and international commerce. Through its dedicated operating subsidiaries, the Group provides outsourced permanent placement services in Singapore and operates an international commodity trading arm focused on the commodities trading business within Asia.

Investor Relations and Media Contact

Ms Emily Choo
Email: emily@gem-comm.com
Mobile: +65 9734 6565

This press release has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the “**Sponsor**”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release. The contact person for the Sponsor is Ms. Lee Khai Yinn (Tel: (65) 6232 3210), at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.